Lisa Astor on Muck Rack

Lisa Astor

New Jersey
As seen in: Targeted Oncology
Covers:  oncology, cancer, healthcare
Associate Editorial Director, Targeted Oncology, @TargetedOnc Passionate about precision medicine in oncology.

Get in touch with Lisa

Contact Lisa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Lisa Astor’s Journalist Portfolio

Update on Frontline Nivolumab/Ipilimumab Combo Demonstrates Positive OS Results in PD-L1+...

Update on Frontline Nivolumab/Ipilimumab Combo Demonstrates Positive OS Results in PD-L1+...

Nivolumab in combination with a low dose of ipilimumab demonstrated an improvement in overall survival compar…

View article →
Pembrolizumab/Lenvatinib Combo Gets FDA Breakthrough Designation for Newly Diagnosed,...

Pembrolizumab/Lenvatinib Combo Gets FDA Breakthrough Designation for Newly Diagnosed,...

Takashi Owa, PhD The FDA has granted a breakthrough therapy designation for the combination of pembrolizumab …

View article →

Articles

Emerging Frontiers in Immunotherapy: The Promise of NK-Cell Therapies

|
By Lisa Astor
| brnw.ch
The landscape of cancer therapy has been witnessing a paradigm shift with the advent of immunotherapy treatments, especially for patients with hematologic malignancies. Immunotherapies such as immune checkpoint inhibitors and autologous chimeric antigen receptor (CAR) T-cell therapies have led to considerable improvements in survival yet still come with efficacy limitations, manufacturing challenges, financial toxicity, and significant safety risks.
Open in Who Shared Issue with article?
See all 1 licensed articles (188 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified